updat solid quarter hiv remain strong new manag horizon
invest summari increas price target
reiter overweight rate gilead beat top bottom line consensu
expect biktarvi launch remain strong hiv price target
higher given revenu trend slightli robust project
compani also increas product revenu guidanc
product revenu ep biktarvi beat
expect report revenu also benefit
gener letairi enter market expect entrant
updat estim quarter new product revenu
estim slightli higher guidanc ep estim
think post solid quarter would expect stock trade
speak manag post call think still earn
inning biktarvi launch still think biktarvi turn
biggest hiv launch one factor allow supersed genvoya
biktarvi like lose share anoth upcom launch
genvoya current compani launch biktarvi germani ex-
us model ww biktarvi revenu ww
estim gilead take share competitor domin share
new start market still probabl remain per year us
gilead believ grow ep trough year
think key swing factor could letairi biktarvi launch expens
manag model ep slightli lower vs
would like see financi engin deal add revenu top
line would assum ep growth howev note hope
may difficult new leadership place given think compani
would wait new manag team
like set-up next six month acknowledg
recent market investor may wait manag
place call gilead note might new manag place
year-end think new leadership place like drive investor
focu thesi next month remain posit think
pipelin expect remain low although see key late-stag catalyst
also think base busi broadli stabil compani
still signific flexibl deal cash balanc
disclosur section may found page
use probability-adjust dcf analysi valu gilead share assum discount rate
model revenu assum termin valu
risk overweight rate price includ hiv gener competit
risk particularli gsk cover brand side slower less success
biktarvi launch expect slow car-t sale current competit emerg
next-gen car-t failur cell therapi modal grow drive stabil growth
long term late-stag pipelin failur particularli nash franchis filgotanib
trial clinic regulatori commerci risk prevent franchis
million except ep
hiv hbv
royalti contract revenu
provis incom tax
net incom gilead non-
net incom non-control interest
net loss non-control interest
growth ep dilut
net incom
non- reconcili
acquisit relat amort intang
acquisition-rel amort inventori mark-up
million except ep
acquisit relat amort intang
non- incom
incom tax effect non-gaap adjust
tax non-gaaap adjust
cog total
 total
sg total
issuanc stock share buyback
chang work capit
present valu flow
npv
npv termin valu
tv
million except ep
growth total hcv
growth total hiv
japan broken
japan broken
epclusa japan
japan
million except ep
million except ep
gilead global biopharmaceut compani major base busi revenu base infecti diseas pipelin
evolv inflamm oncolog nash compani headquart foster citi california
